|Bid||3.3500 x 3100|
|Ask||0.0000 x 1000|
|Day's Range||3.2300 - 3.4800|
|52 Week Range||2.1700 - 53.1000|
|Beta (5Y Monthly)||-1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.98|
JENA, Germany, Jan. 09, 2020 -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development Company announces updated ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment) 78.2% of OLE patients complete extension ...
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identifiedFirst patient treated in Pyoderma.
InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019. The purpose of this study is to investigate the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options. Prof. Niels C. Riedemann, CEO and Founder of InflaRx, commented: “While we were very disappointed about missing our primary endpoint in the SHINE study, our in depth post-hoc data analysis suggests a robust anti-inflammatory activity in the high dose IFX-1 treatment group across numerous efficacy measures which were not reflected by the HiSCR.
Does InflaRx N.V. (NASDAQ:IFRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. Pyoderma Gangraenosum (PG) is a rare and debilitating neutrophilic-driven, autoinflammatory disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs.
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1.
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma.
InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801). AAV is a rare and life-threatening autoimmune disease in which activation of the complement system, and specifically generation of C5a, is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease. The main objective of this randomized, double-blind, placebo-controlled Phase II study is to evaluate the efficacy and safety of IFX-1 in patients with moderate to severe AAV.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1Start of three Phase II trials for IFX-1 in two serious inflammatory.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make moreRead More...
InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the approval of a Clinical Trial Application by Health Canada for a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing IFX-1.
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed as interim Non-Executive Director to the Board of Directors of InflaRx N.V. Mr. Brudnick has substantial experience in the biotechnology and healthcare industry and is currently serving as Chief Business Officer and Head of Strategy for Codiak BioSciences. The confirmed appointment of Mr. Brudnick as a Non-Executive Director of the Board is subject to the approval at the Annual General Meeting of Shareholders in May 2019.
InflaRx shares plummet over 90% after the biotech company said its drug for an inflammatory skin disorder failed to show a show a significant response compared to a placebo. The drug, called IFX-1, is also being tested to treat other skin conditions. Yahoo Finance's Jared Blikre joins Seana Smith.